8-[6-(dimethylamino)-2-methylpyridin-3-yl]-4-(1-ethylbutyl)-2-methylpyrrolo[2,3,4-de]quinolin-5(4H)-one | 1100261-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 8-[6-(dimethylamino)-2-methylpyridin-3-yl]-4-(1-ethylbutyl)-2-methylpyrrolo[2,3,4-de]quinolin-5(4H)-one
• 英文别名: 7-[6-(Dimethylamino)-2-methylpyridin-3-yl]-2-hexan-3-yl-10-methyl-2,9-diazatricyclo[6.3.1.04,12]dodeca-1(11),4(12),5,7,9-pentaen-3-one
• CAS: 1100261-19-5
• 化学式: C₂₅H₃₀N₄O
• 分子量: 402.539
• InChiKey: YWUYYUOKCCTASC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] 8-ARYL-4-ALKYLPYRROLO[2,3,4-DE]QUINOLIN-5(4H)-ONE AND 8-ARYL-4-ALKYL-4,5-DIHYDROPYRROLO[2,3,4-DE]QUINOLIN-5-OL DERIVATIVES<br/>[FR] DÉRIVÉS DE 8-ARYL-4-ALKYLPYRROLO[2,3,4-DÉ]QUINOLÉINE-5(4H)-ONE ET DE 8-ARYL-4-ALKYL-4,5-DIHYDROPYRROLO[2,3,4-DÉ]QUINOLÉINE-5-OL
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2009008552A1

  公开（公告）日：2009-01-15

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. An 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4H)-one or 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivative represented by the following formula [I], has a high affinity for CRF receptors, and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种CRF受体拮抗剂，该拮抗剂作为治疗或预防剂对CRF参与的疾病具有疗效，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、癫痫、皮肤炎、精神分裂症、疼痛等。以下式[I]所代表的8-芳基-4-烷基吡咯并[2,3,4-de]喹啉-5(4H)-酮或8-芳基-4-烷基-4,5-二氢吡咯并[2,3,4-de]喹啉-5-醇衍生物具有高亲和力，对CRF参与的疾病具有疗效。